Fed­er­al judge de­nies Mar­tin Shkre­li all but one mo­tion to dis­miss mo­nop­oly claims in the FTC's Dara­prim law­suit

“Phar­ma Bro” Mar­tin Shkre­li filed mo­tions in May to dis­miss the FTC’s claims that his com­pa­ny Vy­era Phar­ma­ceu­ti­cals boxed out com­pe­ti­tion and cre­at­ed a mo­nop­oly for the tox­o­plas­mo­sis drug Dara­prim af­ter rais­ing prices by 4,000% overnight. But on Tues­day, a fed­er­al judge said not so fast.

Judge Denise Cote de­nied all but one re­quest for dis­missal. The suit was filed in Jan­u­ary by the Fed­er­al Trade Com­mis­sion, New York and oth­er states, which claimed that Shkre­li and co-de­fen­dant Kevin Mul­leady par­tic­i­pat­ed in “an un­law­ful scheme” to hin­der gener­ic com­pe­ti­tion and “pre­serve a mo­nop­oly,” which they al­leged­ly kept go­ing even while Shkre­li was in prison, ac­cord­ing to court doc­u­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER